Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00591747
Other study ID # 1836
Secondary ID 050106
Status Completed
Phase N/A
First received December 31, 2007
Last updated May 26, 2015
Start date November 2005
Est. completion date June 2011

Study information

Verified date May 2015
Source OHSU Knight Cancer Institute
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Women aged 50 and older are disproportionately affected by breast cancer, not only in terms of new diagnoses, but also in terms of survivorship. Approximately 85% of women who receive a first diagnosis of breast cancer are aged 50 and over, thus older women constitute the largest group of breast cancer survivors. Yet, few studies have focused on evaluating whether physical activity and exercise interventions affect long-term symptoms, physical fitness and function, and body composition of older breast cancer survivors. Due to the combined effects of breast cancer, related treatments and aging it is likely that exercise is even more beneficial for older breast cancer survivors than for younger survivors. Along with the cancer-related symptom of fatigue common to cancer survivors, older survivors face age-related declines in bone and muscle mass, muscle strength, bone health and physical function (gait and balance) that are likely exacerbated by reduced physical activity in survivorship and side effects of adjuvant cancer treatment. All women, regardless of age, are at risk for breast cancer recurrence. Recent epidemiologic evidence suggests a link between exercise and reduced risk of cancer recurrence in breast cancer survivors. Strength training is specifically suited to reverse or slow age-related declines in bone, muscle, strength and function and has shown promise to reduce cancer-related fatigue. However, no controlled trials of strength training in older breast cancer survivors have been conducted.


Recruitment information / eligibility

Status Completed
Enrollment 106
Est. completion date June 2011
Est. primary completion date January 2009
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 90 Years
Eligibility Inclusion Criteria:

- Diagnosed with early stage breast cancer at age of 50 or older

- Completed adjuvant therapy, radiation +/- chemotherapy but selective estrogen receptor modulators (SERMS), (aromatase inhibitors (AIs) ok) at least 1 year prior to enrollment

Exclusion Criteria:

- Cognitive difficulties that preclude answering the survey questions, participating in performance testing or giving informed consent

- Diagnosed osteoporosis

- Current regular participation in planned impact activities or resistance training (more than 2 times a week for 30 minutes at a time)

- Medication that contraindicates participation in moderate intensity strength training or previous use of medications known to affect bone metabolism

- Movement or neurologic disorder, not including chemo-induced peripheral neuropathy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care


Intervention

Behavioral:
Resistance Exercise
60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
Flexibility Training
60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.

Locations

Country Name City State
United States OHSU School of Nursing Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute Susan G. Komen Breast Cancer Foundation

Country where clinical trial is conducted

United States, 

References & Publications (4)

Dobek J, Winters-Stone KM, Bennett JA, Nail L. Musculoskeletal changes after 1 year of exercise in older breast cancer survivors. J Cancer Surviv. 2014 Jun;8(2):304-11. doi: 10.1007/s11764-013-0313-7. Epub 2013 Dec 7. — View Citation

Winters-Stone KM, Dobek J, Bennett JA, Nail LM, Leo MC, Schwartz A. The effect of resistance training on muscle strength and physical function in older, postmenopausal breast cancer survivors: a randomized controlled trial. J Cancer Surviv. 2012 Jun;6(2): — View Citation

Winters-Stone KM, Dobek J, Nail L, Bennett JA, Leo MC, Naik A, Schwartz A. Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial. Breast Cancer Res Treat. 2011 Jun;127(2):447-56. doi: — View Citation

Winters-Stone KM, Leo MC, Schwartz A. Exercise effects on hip bone mineral density in older, post-menopausal breast cancer survivors are age dependent. Arch Osteoporos. 2012;7:301-6. doi: 10.1007/s11657-012-0071-6. Epub 2012 Mar 20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Physical functioning (muscle strength, gait and balance), self-report physical and mental health, and fatigue 12 months No
Secondary Body composition (fat mass, muscle mass) and bone mineral density of the lumbar spine and proximal femur 12 months No
See also
  Status Clinical Trial Phase
Completed NCT03273426 - Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy. N/A
Recruiting NCT04583124 - Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO) N/A
Recruiting NCT04489173 - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer Phase 2
Recruiting NCT02913573 - Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction Phase 2
Completed NCT03124095 - Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer N/A
Terminated NCT00251095 - Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer Phase 3
Completed NCT05576545 - Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment N/A
Active, not recruiting NCT03625635 - Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment N/A
Recruiting NCT04799535 - Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Withdrawn NCT03266562 - Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography N/A
Completed NCT00530868 - Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer Phase 2
Recruiting NCT06255808 - Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
Completed NCT04640220 - Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors N/A
Completed NCT02970682 - SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer Phase 2
Completed NCT02316561 - Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer N/A
Terminated NCT00638963 - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) Phase 2
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06056414 - Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation N/A
Recruiting NCT05427071 - Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy N/A
Recruiting NCT03740893 - PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer Phase 2